A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019 Publisher

Shabani M¹ ; Sadegh Ehdaei B² ; Fathi F³ ; Dowran R¹

Source: New Microbes and New Infections Published:2021

Abstract

Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. © 2021 The Authors

Related Docs

View other Related Docs

1. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)

2. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)

3. Drug Repositioning Approach to Target Viral and Host Cells in Terms of Covid-19 Treatment: A Review of in Vivo Experiments and Clinical Studies, Journal of Experimental and Clinical Medicine (Turkey) (2022)

Experts (# of related papers)

View all Related Experts

Hamid Kalantari (2)

Mohammad Minakari (2)

Other Related Docs

4. Erratum: Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase Iii Clinical Trial (Clin Infect Dis (2020) 70:10 (2206-2212) Doi: 10.1093/Cid/Ciz628), Clinical Infectious Diseases (2021)

5. Relative Frequency of Early Virologic Response to Treatment With a Combination of Conventional Interferon and Ribavirin in Patients With Chronic Hepatitis C, Journal of Isfahan Medical School (2012)

6. A Multicenter Study to Evaluate the Safety and Efficacy of Heberon (Interferon Alfa-2B) in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Iran, Medical Journal of the Islamic Republic of Iran (2005)

7. New Treatments (Msc) in Immune Disorders Like Cancers and Covid Infection: Cancer and Virus New Treatment (Msc), Asia Pacific Journal of Cancer Biology (2024)

8. The Correlation Between Viral Shedding Duration and Blood Biomarkers in Covid-19-Infected Patients, Journal of Research in Medical Sciences (2022)

9. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)

10. Effectiveness of Corticosteroid Therapy in Patients With Moderate to Severe Coronavirus Disease 2019: A Retrospective Study, Journal of Nephropharmacology (2023)

11. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in Sars-Cov-2: Design Strategies and Challenges for Targeted Delivery, Current medicinal chemistry (2025)

12. Vaccine Production by Recognizing the Functional Mechanisms of Covid-19, Translational Research in Urology (2020)

13. Sars-Cov-2 Vaccines: A Double-Edged Sword Throughout Rapid Evolution of Covid-19, Cell Biology International (2022)

14. Novel Drug Design for Treatment of Covid-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology (2022)

15. Potential Inhibitors of Sars-Cov-2: Recent Advances, Journal of Drug Targeting (2021)

16. Covid-19 Pandemic: Insights Into Genetic Susceptibility to Sars-Cov-2 and Host Genes Implications on Virus Spread, Disease Severity and Outcomes, Human Antibodies (2022)

17. Emerging Technologies for the Treatment of Covid-19, Advances in Experimental Medicine and Biology (2021)

18. Ethanol Inhalation for Respiratory Infections Due to Enveloped Viruses, Infectious Diseases and Therapy (2025)

19. Therapeutic Targets of Natural Products for the Management of Cardiovascular Symptoms of Coronavirus Disease 2019, Phytotherapy Research (2021)

20. A Comprehensive Review of Therapeutic Options for Covid-19, Ethiopian Journal of Health Development (2022)

Style	Citing Format
MLA	Shabani M, et al.. "A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019." New Microbes and New Infections, vol. 42, no. , 2021, pp. -.
APA	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R (2021). A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019. New Microbes and New Infections, 42(), -.
Chicago	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. "A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019." New Microbes and New Infections 42, no. (2021): -.
Harvard	Shabani M et al. (2021) 'A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019', New Microbes and New Infections, 42(), pp. -.
Vancouver	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019. New Microbes and New Infections. 2021;42():-.
BibTex	@article{ author = {Shabani M and Sadegh Ehdaei B and Fathi F and Dowran R}, title = {A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019}, journal = {New Microbes and New Infections}, volume = {42}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Shabani M AU - Sadegh Ehdaei B AU - Fathi F AU - Dowran R TI - A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019 JO - New Microbes and New Infections VL - 42 IS - SP - EP - PY - 2021 ER -